HK164195A - Novel polypeptide - Google Patents

Novel polypeptide

Info

Publication number
HK164195A
HK164195A HK164195A HK164195A HK164195A HK 164195 A HK164195 A HK 164195A HK 164195 A HK164195 A HK 164195A HK 164195 A HK164195 A HK 164195A HK 164195 A HK164195 A HK 164195A
Authority
HK
Hong Kong
Prior art keywords
novel polypeptide
polypeptide
novel
Prior art date
Application number
HK164195A
Other languages
English (en)
Inventor
Tetsuro Kuga
Yoshinori Komatsu
Horomasa Miyaji
Moriyuki Sato
Masami Okabe
Makoto Morimoto
Seiga Itoh
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17961392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK164195(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of HK164195A publication Critical patent/HK164195A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK164195A 1986-12-23 1995-10-19 Novel polypeptide HK164195A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30679986 1986-12-23

Publications (1)

Publication Number Publication Date
HK164195A true HK164195A (en) 1995-10-27

Family

ID=17961392

Family Applications (1)

Application Number Title Priority Date Filing Date
HK164195A HK164195A (en) 1986-12-23 1995-10-19 Novel polypeptide

Country Status (10)

Country Link
EP (1) EP0272703B2 (es)
JP (1) JPH068317B2 (es)
KR (1) KR960016560B1 (es)
CA (1) CA1341522C (es)
DE (1) DE3786767T3 (es)
DK (1) DK174044B1 (es)
ES (1) ES2059354T5 (es)
HK (1) HK164195A (es)
NO (1) NO176799C (es)
PT (1) PT86465B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
US5298603A (en) * 1985-12-21 1994-03-29 Hoechst Aktiengesellschaft GM-CSF protein, its derivatives, the preparation of proteins of this type, and their use
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5688768A (en) * 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
US7119182B1 (en) 1991-02-19 2006-10-10 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
DK0744409T3 (da) 1994-02-23 2008-11-10 Kyowa Hakko Kogyo Kk Accelerator for vækst af blodplader
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6100070A (en) * 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
DE19860801A1 (de) * 1998-12-30 2000-07-06 Rhein Biotech Proz & Prod Gmbh Rekombinanter Wachstumsfaktor mit der biologischen Aktivität eines G-CSF (Granulocyte Colony Stimulating Factor)
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
JP4799803B2 (ja) 2000-09-08 2011-10-26 マサチューセッツ インスティテュート オブ テクノロジー Ｇ−ｃｓｆアナログ組成物および方法
DE60227367D1 (de) 2001-02-06 2008-08-14 Merck Patent Gmbh Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
IL159524A0 (en) 2001-07-11 2004-06-01 Maxygen Holdings Ltd G-csf conjugates
EP1490402A4 (en) 2002-03-20 2007-05-02 Biopolymed Inc PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) * 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
JP4607010B2 (ja) 2003-02-28 2011-01-05 中外製薬株式会社 タンパク質含有安定化製剤
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060153799A1 (en) 2004-11-05 2006-07-13 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
RU2007149238A (ru) 2005-06-01 2009-07-20 Максиджен Холдингз Лтд. (Ky) Пегилированные полипептиды гксф и способы их получения
WO2008075371A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for immunomodulation
AU2008287063B2 (en) 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
WO2010092571A2 (en) 2009-02-11 2010-08-19 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
ES2654102T3 (es) 2010-01-19 2018-02-12 Hanmi Science Co., Ltd. Formulaciones líquidas para conjugado de C-CSF de acción prolongada
NZ602255A (en) 2010-03-04 2014-04-30 Pfenex Inc Method for producing soluble recombinant interferon protein without denaturing
US8455218B2 (en) 2010-04-01 2013-06-04 Pfenex, Inc. Methods for G-CSF production in a Pseudomonas host cell
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2017009843A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
MX2018010125A (es) 2016-02-23 2019-03-28 Biolinerx Ltd Procedimientos de tratamiento de leucemia mieloide aguda.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4869987A (es) 1971-12-27 1973-09-22
JPS58110600A (ja) 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
DE3680613D1 (de) * 1985-02-08 1991-09-05 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
EP0256843A1 (en) 1986-08-11 1988-02-24 Cetus Corporation Expression of g-csf and muteins thereof and their use
JP2581110B2 (ja) * 1987-10-26 1997-02-12 いすゞ自動車株式会社 パティキュレートトラップの再燃焼装置

Also Published As

Publication number Publication date
KR960016560B1 (ko) 1996-12-14
NO875378L (no) 1988-06-24
EP0272703B1 (en) 1993-07-28
DE3786767T2 (de) 1994-01-13
EP0272703B2 (en) 1997-10-15
NO176799C (no) 1995-05-31
DE3786767D1 (de) 1993-09-02
ES2059354T5 (es) 1998-03-16
DE3786767T3 (de) 1998-04-16
DK174044B1 (da) 2002-05-06
JPS63267292A (ja) 1988-11-04
JPH068317B2 (ja) 1994-02-02
KR880007734A (ko) 1988-08-29
DK680987A (da) 1988-06-24
NO875378D0 (no) 1987-12-22
PT86465B (pt) 1990-11-20
EP0272703A1 (en) 1988-06-29
CA1341522C (en) 2007-03-13
NO176799B (no) 1995-02-20
ES2059354T3 (es) 1994-11-16
PT86465A (en) 1988-01-01
DK680987D0 (da) 1987-12-22

Similar Documents

Publication Publication Date Title
HK164195A (en) Novel polypeptide
GR871567B (en) Polypeptide derivatives
ZA878336B (en) Peptides
PH23573A (en) Novel dialkylmaleimides
GB8616166D0 (en) Polypeptide competitor
ZA876543B (en) Novel 4-methylphthalimides
IL84818A0 (en) Novel dihydrothiadiazoles
ZA874454B (en) Novel vaccenes
ZA873796B (en) Peptides
ZA878945B (en) Peptides
GB8723507D0 (en) Polypeptide
GB8715737D0 (en) Polypeptide
GB8725462D0 (en) Protein
GB8725463D0 (en) Protein
PT84118B (en) Polypeptide compounds
GB2198131B (en) Novel prostacyclines
GB8626622D0 (en) Polypeptides
GB8627675D0 (en) Polypeptide
ZA877826B (en) Polypeptide preparation
GB2198130B (en) Novel prostacyclines
IE862882L (en) Polypeptides
IE860720L (en) Polypeptides
GB8619842D0 (en) Peptides
GB8623237D0 (en) Peptides
IE863014L (en) Peptides

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20071222